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Abstract
Purpose The study aimed to analyze clinicopathological fac-
tors that determine the extent of lymph node retrieval and to
evaluate its prognostic impact in patients with colorectal can-
cer (CRC).
Methods The number of retrieved lymph nodes was analyzed
in 381 CRC specimens. Lymph node count was related to
different clinicopathological variables by binary logistic re-
gression. Progression-free survival (PFS) and cancer-specific
survival (CSS) were determined using the Kaplan-Meier
method and Cox regression models.
Results The median number of retrieved lymph nodes was 20
(mean 21 ± 10, range 1–65) in right-sided, 13 (16 ± 10, 1–66)
in left-sided, and 15 (18 ± 11, 3–64) in rectal tumors. The
number of retrieved lymph nodes was independently associ-
ated with T-classification (p < 0.001), N-classification
(p = 0.014), and tumor size (p = 0.005) as well as right-
sided tumor location (p = 0.012). There was no association
with age, sex, tumor grade, mismatch-repair status, and lymph
or blood vessel invasion. The longer the surgical specimen,
the higher were the numbers of retrieved and positive lymph
nodes (p < 0.001, respectively). In patients with locally ad-
vanced (T3/T4) tumors (n = 283), analysis of more than 12
lymph nodes was independently associated with PFS
(HR = 0.63, p = 0.025) and CSS (HR = 0.54, p = 0.004). In
the subset of T3/T4 N0 patients (n = 130), analysis of more
than 12 lymph nodes similarly proved to be an independent
predictor of outcome (PFS, HR = 0.48, p = 0.046; OS,
HR = 0.41, p = 0.026).
Conclusion The number of retrieved lymph nodes is associ-
ated with higher tumor stage, tumor size, and right-sided lo-
cation. Low lymph node count indicates adverse outcome in
patients with locally advanced (T3/T4) disease.
Keywords Lymph node . Prognostic factor . Colon cancer .
Rectum cancer .Multivariate analysis
Introduction
Colorectal cancer (CRC) is globally the third most commonly
diagnosed cancer in males and the second most common in
females [1]. It is thus a major contributor to cancer morbidity
and mortality worldwide.
In CRC, the involvement of lymph nodes by tumor cells
represents a major step to systemic tumor spread and is there-
fore a strong indicator of adverse prognosis [2]. Lymph node
involvement is a determining variable of the AJCC/UICC
TNM system, which is currently the most relevant prognostic
classification and used as basis for therapeutic decisions [3, 4].
Specifically, patients without evidence of distant metastasis
undergoing resection for primary colon cancer may receive
adjuvant chemotherapy mainly based upon the identification
of metastatic lymph nodes [5].
Adequate lymphadenectomy and sufficient lymph node re-
trieval from the resected specimen are crucial to ensure
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accuracy in staging, especially to prevent under-diagnosis of
lymph node involvement by tumor cells [6, 7]. Additionally, a
higher number of sampled lymph nodes has emerged as inde-
pendent prognostic factor for improved survival in several pre-
vious studies, especially in stage II CRC [6–11]. Hence, adju-
vant chemotherapy has been recommended by current practice
guidelines in case of inadequately sampled numbers of lymph
nodes, even if no involvement of lymph nodes by tumor cells is
found [12]. However, data are conflicting, and not all studies
showed improved outcome for CRC patients when more
lymph nodes had been retrieved [13–15]. The number of re-
trieved lymph nodes may depend on different factors, including
surgical radicality and dedicated pathological work-up, but also
on patient- and tumor-specific factors [6, 7].
International guidelines currently recommend sampling of
a minimum number of 12 lymph nodes. Evidence, however, is
weak, and it is not known, whether the sampling of more than
12 nodes improves staging accuracy and prognosis [6, 7]. It is
therefore an ongoing debate how many lymph nodes need to
be sampled for optimal staging. It is likewise unclear whether
the cut-off value of 12 nodes should be adjusted by patient- or
tumor-specific factors.
Therefore, our study aimed to analyze different clinicopath-
ological factors that determine the extent of lymph node re-
trieval and to evaluate the prognostic impact of the extent of
lymph node retrieval in a large cohort of CRC patients.
Patients and methods
Patient cohort
Our cohort consisted of 381 patients including 166 (44%)
females and 215 (56%) males (ratio 1:1.3). Mean age was
68.5 years (median 70.1, range 28–93). Case selection of our
cohort has been described in detail previously [16]. Briefly,
400 CRC patients treated from January 1992 through
December 2000 at one institution (Medical University of
Graz, Austria) were randomly selected from the CRC database
of the Institute of Pathology, Medical University of Graz. We
excluded patients with T1 cancer treated by endoscopic
polypectomy, patients that received neoadjuvant chemothera-
py or radiotherapy, and patients with syn- or metachronous
invasive cancers originating from the colorectum or other
sites. In total, 381 resection specimens from 400 patients
(95%) were available for review pathology. AJCC/UICC
stage determined treatment of our patients. Stage III patients
received adjuvant chemotherapy with 5-fluorouracil/folinic
acid according to the Mayo Clinic regimen [17]. Stage I and
II patients did not receive adjuvant therapy. Patients with stage
IV disease were treated with different combination chemo-
therapy regimens according to the choice of the treating phy-
sician. Follow-up of our cohort has been described in a
previous publication [16]. It included at least chest X-rays
and abdominal ultrasound every 6 months for the first 3 years
and yearly thereafter. Disease progression was defined as local
tumor recurrence or development of distant metastasis.
The investigation was carried out in accordance with the
Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Medical University of
Graz, Austria. For this retrospective study, formal consent of
each patient is not required.
Pathological evaluation
Original histopathological slides were independently re-
evaluated by two gastrointestinal pathologists (M.J.P. and
C.L.). Tumor stage was assessed according to the 7th edition
of the AJCC/UICC TNM classification [4]. Histological tu-
mor type and tumor grade were analyzed according to the
WHO guidelines [18]. Tumors located in the rectum or at
the rectosigmoid junction were summarized as rectal cancers.
Tumors originating from sigmoid colon to the left colonic
flexure were defined as left-sided cancers, while tumors locat-
ed from transverse colon to caecum were defined as right-
sided cancers. The presence of lymph and/or blood vessel
invasion was assessed as carcinoma being present in vessels
with an unequivocal endothelial lining (lymphatic invasion) or
in vessels with a thick vascular wall and red blood cells in the
lumen (blood vessel invasion) [16]. Mismatch-repair (MMR)
status was assessed by immunohistochemistry as described
earlier, using antibodies directed against MLH1, MSH2, and
MSH6 [19]. The loss of immunoreactivity for at least one of
the three markers characterized MMR-deficient tumors [20].
No special fat clearance or staining techniques were used for
lymph node harvesting.
Statistical analysis
Associations with AJCC/UICC stage, T-classification, N-clas-
sification, grade, MMR status, location, tumor size, lymphatic
invasion, and venous invasion were analyzed using the Chi
square test or Student’s t test. Coefficients of correlation were
determined by Pearson’s r. Binary logistic regression model
including an intercept was applied to assess the influence of
primary tumor characteristics on the number of retrieved
lymph nodes. The Hosmer-Lemeshow-test was used to assess
goodness of fit of the model. Cause of death was determined
by treating physicians and/or by chart review and was corrob-
orated by death certificates if available. Progression-free sur-
vival (PFS) and cancer-specific survival (CSS) were investi-
gated using the Kaplan-Meier method and compared by the
log-rank test. For multivariable testing, Cox proportional haz-
ards regression models were performed. Statistical calcula-
tions were performed using SPSS version 20.0 (IBM,
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Armonk, NY, USA). All reported p values were two-sided
with significance at p < 0.05.
Results
Amean number of 18.1 ± 10.7 lymph nodes (median 16, range
1–66) were retrieved in our patients. Specifically, the number
was 21 ± 10.5 (median 20, range 1–65) in right-sided, 15.6 ± 9.8
(13, 1–66) in left-sided, and 17.9 ± 11 (15, 3–64) in rectal
tumors (Fig. 1a). Twelve or more lymph nodes were sampled
in 270 (70.9%) cases. Positive lymph nodes were detected in
168 (44%) patients. The number of retrieved lymph nodes was
higher in patients with lymph node positive tumors compared
with patients with lymph node negative tumors (mean 20 ± 11.8
versus 16.6 ± 9.5; p = 0.002, Fig. 1b). This difference was
particularly pronounced in patients with rectal cancer (N0
15.4 ± 9.3 retrieved lymph nodes versus N1/2 20.9 ± 12.3,
p = 0.001) and almost significant in left-sided colon cancers
(N0 14.1 ± 8.9 versus N1/2 17.5 ± 10.6, p = 0.075), while no
difference was observed in right-sided cancers (N0 20.7 ± 9.1
versus N1/2 21.5 ± 12.1, p = 0.707, Fig. 1c–e).
We categorized the number of retrieved lymph nodes into
four groups (1–9, 10–19, 20–29, and >29). With this classifi-
cation, a higher number of sampled nodes was significantly
associated with higher T-classification (p < 0.001), higher
AJCC/UICC stage (p < 0.001), larger tumor size
(p = 0.030), and right-sided tumor location (p < 0.001).
Association with N-classification was nearly significant
(p = 0.059). There was no association with age, sex, grade,
mismatch-repair status, and lymph or blood vessel invasion
(Table 1).
In a binary logistic regression model, tumor size, T-classi-
fication, N-classification, and right tumor localization proved
to be to independently associated with the retrieval of more
than the recommended 12 lymph nodes (Table 2).
Of note, the length of the surgical resection CRC specimen
(data available for 359 patients) correlated positively with the
number of retrieved lymph nodes (r = 0.436; p < 0.001) and
with the number of lymph nodes involved by tumor cells
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Fig. 1 Numbers of retrieved
lymph nodes in right-sided colon
cancers, left-sided colon cancers,
and rectum cancers (a). Numbers
of retrieved lymph nodes in
patients with node negative and
node positive tumors analyzing
all cases (b). Restricted to right-
sided tumors (c). Restricted to
left-sided tumors (d). Restricted
to rectum cancers (e)
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the higher was the number of retrieved and also the number of
positive lymph nodes (Fig. 2).
Survival analysis
Analyzing 350 out of 381 (92%) patients with available
follow-up data, we observed progressive disease in 141
(40%) patients after a mean (median) follow-up of 56
(45) months (range 1–182). Mean time to progression was
15 months (median 7, range 0–88). At the end of follow-up,
118 (34%) patients had died from cancer [16].
Disease progression occurred in 42.5, 36.1, 40, and
47.5% of patients with 1–9, 10–19, 20–29, and >29 sam-
pled lymph nodes (p = 0.684), respectively. In addition,
34.3, 32.2, 33.0, and 37.5% of patients with 1–9, 10–19,
20–29, or >29 retrieved lymph nodes died of disease
(p = 0.885).
When we analyzed our cohort using the cut-off of 12
lymph nodes recommended by the AJCC/UICC TNM staging
system, we observed disease progression in 41.2% of patients
with ≤12 compared with 39% of patients with >12 retrieved
lymph nodes (p = 0.563). In addition, 32.8% of patients with
≤12 and 33.8% of patients with >12 retrieved lymph nodes
died of disease (p = 0.879).
When we restricted analysis to patients with T3 or T4 tu-
mors irrespective of nodal status (n = 283), we observed dis-
ease progression in 57.8% of patients with ≤12 compared with
46.6% of patients with >12 retrieved lymph nodes (p = 0.044;
Table 1 Associations of the number of retrieved lymph nodes with different clinicopathological parameters
1–9 Lymph nodes 10–19 Lymph nodes 20–29 Lymph nodes >29 Lymph nodes p value
Age ≤70 40 (21.1%) 77 (40.5%) 51 (26.8%) 22 (11.6%) 0.95
>70 39 (20.4%) 83 (43.5%) 48 (25.1%) 21 (11%)
Sex Female 40 (18.6%) 96 (44.7%) 56 (26%) 23 (10.7%) 0.56
Male 39 (23.5%) 64 (38.6%) 43 (25.9%) 20 (12%)
T-classification 1 12 (42.9%) 13 (46.4%) 2 (7.1%) 1 (3.6%) <0.001
2 23 (32.9%) 39 (55.7%) 5 (7.1%) 3 (4.3%)
3 37 (17%) 82 (37.6%) 74 (33.9%) 25 (11.5%)
4 7 (10.8%) 26 (40%) 18 (27.7%) 14 (21.5%)
N-classification 0 51 (23.9%) 94 (44.1%) 49 (23%) 19 (8.9%) 0.059
1 19 (22.9%) 28 (33.7%) 26 (31.3%) 10 (12%)
2 9 (10.6%) 38 (44.7%) 24 (28.2%) 14 (16.5%)
AJCC/UICC stage I 27 (33.3%) 45 (55.6%) 6 (7.4%) 3 (3.7%) <0.001
II 18 (15%) 47 (39.2%) 40 (33.3%) 15 (12.5%)
III 20 (15.9%) 50 (39.7%) 38 (30.2%) 18 (14.3%)
IV 14 (25.9%) 18 (33.3%) 15 (27.8%) 7 (13%)
Tumor grade 1 35 (23.5%) 58 (38.9%) 43 (28.9%) 13 (8.7%) 0.27
2 29 (20%) 66 (45.5%) 36 (24.8%) 14 (9.7%)
3 10 (16.4%) 28 (45.9%) 11 (18%) 12 (19.7%)
4 5 (19.2%) 8 (30.8%) 9 (34.6%) 4 (15.4%)
L L0 50 (19.6%) 112 (43.9%) 69 (27.1%) 24 (9.4%) 0.27
L1 29 (23%) 48 (38.1%) 30 (23.8%) 19 (15.1%)
V V0 62 (21.1%) 124 (42.2%) 77 (26.2%) 31 (10.5%) 0.87
V1 17 (19.5%) 36 (41.4%) 22 (25.3%) 12 (13.8%)
Tumor size ≤4.5 28 (30.8%) 38 (41.8%) 18 (19.8%) 7 (7.7%) 0.030
>4.5 51 (17.6%) 122 (42.1%) 81 (27.9%) 36 (12.4%)
Tumor location Right 13 (12.1%) 34 (31.8%) 43 (40.2%) 17 (15.9%) <0.001
Left 35 (31.8%) 44 (40%) 23 (20.9%) 8 (7.3%)
Rectum 31 (18.9%) 82 (50%) 33 (20.1%) 18 (11%)
MMR status Deficient 5 (21.7%) 10 (43.5%) 6 (26.1%) 2 (8.7%) 0.95
Proficient 72 (20.6%) 147 (42%) 90 (25.7%) 41 (11.7%)
Table 2 Binary logistic regression analysis of factors predicting
retrieval of ≥12 lymph nodes in CRC
Variable Level HR CI p value
Tumor size >4.5 2.12 1.26–3.56 0.005
T-classification >2 2.87 1.70–4.85 <0.001
N-classification Positive 1.89 1.14–3.13 0.014
Location Right 2.04 1.18–3.57 0.012
HR hazard ratio, CI confidence interval
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Fig. 3a). Actuarial 5-year PFS rates were 42 and 52%, respec-
tively. In addition, 48.4% of patients with ≤12 and 39.8% of
patients with >12 retrieved lymph nodes died of disease
(p = 0.029; Fig. 3b). Actuarial 5-year CSS rates were 52 and
61%, respectively.
In patients with T3/T4, N0 disease (n = 130), disease pro-
gression occurred in 40% of patients with ≤12 compared with
21.6% of patients with >12 retrieved lymph nodes (p = 0.037;
Fig. 3c). Actuarial 5-year PFS rates were 60 and 81%, respec-
tively. In addition, 36.6% of patients with ≤12 and 18.2% of

















Fig. 3 Progression-free (a) and cancer-specific survival (b) of patients
with T3/T4 cancer related to the number of retrieved lymph nodes (≤12
versus >12 nodes); progression-free (c) and cancer-specific survival (d) of
patients with T3/T4 N0 cancer related to the number of retrieved lymph
nodes (≤12 versus >12 nodes)
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patients with >12 retrieved lymph nodes died of disease
(p = 0.029; Fig. 3d). Actuarial 5-year CSS rates were 67 and
84%, respectively.
In Cox proportional hazards regression analysis, lymph
node retrieval prove to be an independent prognostic factor
for PFS and CSS of patients with T3/T4 tumors irrespective of
nodal involvement (Table 3). When we performed Cox anal-
ysis in T3/T4 N0 patients, again lymph node retrieval proved
to be an independent prognostic variable for PFS (HR = 0.48,
95% CI = 0.23–0.99, p = 0.046) and OS (HR = 0.41, 95%
CI = 0.19–0.90, p = 0.026), while age >70 years, female gen-
der and grading did not show independent prognostic impact
for both PFS (p = 0.84, p = 0.82, and p = 0.75, respectively) or
OS (p = 0.47, p = 0.95, and p = 0.51, respectively).
Discussion
The prognosis of patients with CRC after tumor resection
depends substantially on the presence of lymph nodes in-
volved by tumor cells. The number of sampled (that is the
number of histologically analyzed) lymph nodes has therefore
been discussed as marker for adequate staging, quality of sur-
gical therapy and pathological work-up, but also as indepen-
dent prognostic marker guiding therapeutic decisions [6, 7].
According to our data, retrieval of more than 12 lymph nodes
proved to be a significant prognostic factor in locally advanced
(T3/T4) CRC in both univariable and multivariable analyses.
Moreover, high T-classification and tumor stage, tumor size
and location, as well as length of the resection specimen were
all significantly associated with lymph node count. In concor-
dance with our data, a systematic review [8] and further recent
studies [9, 21–24] demonstrated significant prognostic impact
of lymph node count in stage II disease. A reason for this may
be the better selection of patients who are truly node negative
and are thus cured by surgery alone [7]. However, this view has
been challenged by publications arguing that a higher number of
retrieved lymph nodes did not increase the proportion of stage
III disease [25, 26]. Also, in stage III cases and in mixed pop-
ulations, several studies showed significant prognostic impact
[8–11, 27, 28]. A more thorough clearance of tumor cells by
improved lymphadenectomy may explain the observed prog-
nostic influence [7]. Accordingly, studies including ours, have
demonstrated an association of lymph node retrieval with the
length of the examined operation specimen [13, 24, 29–31].
However, independent of surgical extent und thoroughness
of the pathological work-up, tumor- and/or patient-specific fac-
tors are influencing lymph node retrieval in colorectal cancer.
According to our data, a higher number of lymph nodes was
harvested in patients with lymph node involvement by tumor.
This association has been reported previously [11, 21, 23];
however, not all studies showed this association [10].
Furthermore, T-classification and higher tumor stage were sig-
nificantly associated with higher lymph node count. Both asso-
ciations are in the line with literature data showing associations
of lymph node retrieval with T-classification [13, 21, 23, 32]
andAJCC/UICC stage [11, 13, 14, 21, 32–35]. Also, tumor size
is, according to previous studies, an established predictor of
lymph node yield [11, 13, 23, 29, 31, 36] that could be con-
firmed by our study. Other previously described factors were
not found to be related to lymph node yield in our study. For
instance, younger patient age has repeatedly been reported to be
significantly associated with lymph node count [9, 11, 13, 14,
23, 29, 31–33, 35, 37], but not in our cohort.
Another interesting determining factor for lymph node yield is
tumor location. Apart from our analysis, several other studies
have demonstrated higher numbers of lymph nodes retrieved
from patients with right-sided, compared with left-sided cancers
[9, 13, 29, 32, 34–38]. Differences in embryonic development or
a greater length of the mesenteric root have been discussed as
possible cause [7]. However, also a higher inflammatory re-
sponse to right-sided tumors, which are often microsatellite in-
stable, has been proposed and found in previous analyses [36,
39].Wewere not able to prove this association, but the number of
mismatch-repair deficient tumors was rather low in our cohort.
Since patient- and tumor-related factors play a major role
for lymph node retrieval, the value of efforts, which aim to
increase the lymph node yield, has been challenged [40]. Also,
since several studies failed to prove prognostic impact [13–15,
34, 36, 40]. These negative results may be due to different
Table 3 Multivariable analysis
of prognostic factors for PFS and
CSS in T3/T4 CRCs
PFS CSS
Variable Level HR CI p value HR CI p value
Age >70 1.15 0.80–1.63 0.45 1.51 1.03–2.20 0.036
Gender Female 1.13 0.79–1.62 0.51 1.18 0.80–1.74 0.41
Grade >2 1.24 0.86–1.77 0.25 1.75 1.19–2.58 0.004
N-retrieval >12 0.63 0.43–0.95 0.025 0.54 0.35–0.82 0.004
N-classification >0 4.32 4.31–2.84 <0.001 4.61 2.95–7.21 <0.001
PFS progression-free survival, CSS cancer-specific-survival, HR hazard ratio, CI confidence interval, N-retrieval
lymph node retrieval
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methodologies and heterogeneous study populations includ-
ing different stages, both colon and rectum cancers, different
cut-off values, but also small sample sizes. Of note, median
numbers of retrieved lymph nodes vary greatly among pub-
lished reports, according to a review by McDonald et al. [6]
ranging from 6 to 21.
It has to be mentioned as limitation that our study cohort is
heterogeneous with respect to inclusion of both, colon and rec-
tum cancers. We excluded patients with rectal cancer that had
undergone neoadjuvant chemotherapy or radiotherapy before
surgery to keep our study cohort more homogenous. Of note,
previous studies have revealed lower numbers of retrieved
lymph nodes after neoadjuvant treatment [21, 23, 33, 41].
Another limitation of our study is the retrospective character
of our analysis. Previous studies have shown that factors related
to surgical procedure were related to lymph node harvest, in-
cluding open versus laparoscopic approach. Those factors
could not be analyzed here in detail as data were not available
in this regard. Of note, with complete mesocolic excision
(CME), a standardized surgical procedure is now available that
leads to better surgical specimens and allows improved quality
control. Therefore, future studies dealingwith lymph node yield
in colon cancer surgery should be done with pathologically
graded CME specimens to increase comparability [42].
In conclusion, higher AJCC/UICC stage, tumor size, and
right-sided location, as well as the length of the operation spec-
imen were factors associated with lymph node retrieval.
Rational cut-off values defining theminimum number of lymph
nodes to be assessed for staging of CRC may thus be adjusted
by these variables. According to our data, analysis of more than
12 lymph nodes is significantly associated with improved out-
come in patients with locally advanced (T3/T4) disease.
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